ADPS™
BRAF Mutation Test Kit v2
Ultra-Sensitivity Enhancing BRAF Research Outcomes
Ultra-Sensitivity Enhancing BRAF Research Outcomes
BRAF is a serine/threonine kinase that functions in the Ras-Raf-MEK-MAPK pathway and has been implicated in cancer development. The most common BRAF mutation, BRAF V600, results in the permanent activation of the BRAF protein without growth factors, leading to excessive cell proliferation and resistance to apoptosis.
BRAF mutations are commonly found in thyroid cancer and cutaneous melanoma. They are reported to occur at a frequency of approximately 35% in melanoma and 65% in thyroid cancer. Treatments targeting BRAF have shown clinical benefit in most patients with BRAF V600 mutations.
The ADPS™ BRAF Mutation Test Kit v2 is designed for accurate identification of mutations, playing a critical role in the administration of TKI therapy. The enhanced version of the product detects mutations with a sensitivity of up to 0.02%, providing results that clearly distinguish between V600E and V600K mutations, confirming the presence of each mutation.
This product is for research use only (RUO) and not intended for use in diagnostic procedures.
| Catalog No. | (RUO) R8004CPA |
|---|---|
| Detection target | B3 mutations in BRAF V600 codon (two V600E and V600K mutations) |
| Assay type | qPCR |
| Sample type | DNA extracted from FFPE, frozen, and fresh cancer tissue or liquid biopsy |
| Master Mixture (MMX) |
2MMXs |
| Internal Control | BRAF intron 1 |
| Detection Sensitivity | V600E: 0.02%, V600K: 0.05% |
| Detection Specificity | ≥ 99.3% |
| Precision (% CV) | ≤ 5% (CV, coefficient of variation) |
| Storage | -20±5℃ |
| Stability | 18 months |
| Freeze/Thaw stability | 5 times |
| Compatible Instruments | AB 7500 Fast, CFX96, QuantStudio 5 |
ADPS™ Oncogene Mutation Test